Protagonist Therapeutics Files 8-K on Financials

Ticker: PTGX · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1377121

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

Protagonist Therapeutics filed an 8-K for financial reporting on Feb 21, 2025.

AI Summary

Protagonist Therapeutics, Inc. filed an 8-K on February 21, 2025, reporting on its results of operations and financial condition, and providing financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the reporting of these items.

Why It Matters

This filing indicates that Protagonist Therapeutics is providing updates on its financial condition and operations to the SEC, which is standard for public companies.

Risk Assessment

Risk Level: low — This is a routine financial filing with no new material information or significant events disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Protagonist Therapeutics, Inc., and to provide Financial Statements and Exhibits.

On what date was this 8-K filing reported?

The earliest event reported in this 8-K filing was on February 21, 2025.

In which state is Protagonist Therapeutics, Inc. incorporated?

Protagonist Therapeutics, Inc. is incorporated in Delaware.

What is the Commission File Number for Protagonist Therapeutics, Inc.?

The Commission File Number for Protagonist Therapeutics, Inc. is 001-37852.

What is the IRS Employer Identification Number for Protagonist Therapeutics, Inc.?

The IRS Employer Identification Number for Protagonist Therapeutics, Inc. is 98-0505495.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding Protagonist Therapeutics, Inc (PTGX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing